
Organogenesis Holdings (ORGO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Organogenesis Holdings (ORGO) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided revenue in the range of $179M - $215M for the period.
Compared to prior guidance, Organogenesis Holdings lowered its revenue forecast from a prior range of $270M - $310M.
Organogenesis Holdings has issued 15 guidance updates between November 9, 2022 and August 6, 2026. During this period, the company raised its outlook 4 times and lowered it 5 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.35 | $-0.29 | $0.21 | $0.07 |
| Actual | $-0.69 | $-0.34 | $0.40 | $0.18 |
| Surprise | -97.1% | -17.2% | +90.5% | +152.9% |
| Revenue | ||||
| Estimate | $54.3M | $43.3M | $172.7M | $134.1M |
| Actual | $100.8M | $36.3M | $225.6M | $150.9M |
| Surprise | +85.7% | -16.3% | +30.6% | +12.5% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.17 | $-0.14 |
| Revenue | ||
| Consensus | $52.1M | $63.0M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.69 | $-0.35 | -97.1 % |
| Q1 | May 7, 2026 | $-0.34 | $-0.29 | -17.2 % |
| Q4 | Feb 26, 2026 | $0.40 | $0.21 | 90.5 % |
| Q3 | Nov 6, 2025 | $0.18 | $0.07 | 152.9 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $100.78M | $54.28M | 85.7 % |
| Q1 | May 7, 2026 | $36.25M | $43.30M | -16.3 % |
| Q4 | Feb 26, 2026 | $225.61M | $172.68M | 30.6 % |
| Q3 | Nov 6, 2025 | $150.86M | $134.10M | 12.5 % |